Health Condition 1: H162- Keratoconjunctivitis
Conditions
Interventions
Intervention1: CYCLOSPORINE: One drop of CYCLOSPORINE (0.05%) in each eye to be instilled twice a day (once on waking in the
morning and once at bedtime) for one month
Control Intervention1: RESTASISÂ
Sponsors
New India Bio Pharma Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1.Male or female, between 18 and 65 years of age (both age inclusive). 2.Subjects presenting with documented signs and symptoms of moderate to severe Keratoconjunctivitis sicca (KCS) by diagnostic criteria as per investigators discretion. 3.History of KCS for a period of at least 6 months 4.Lack of clinically adequate improvement despite conventional management, which may have included artificial tear eye drops, topical parasympathomimetic agentâ??s topical steroids in the affected eye(s). 5. Schirmer Tear Test (ST) score (without anesthesia) 6. Positive corneal staining, defined as a corneal fluorescein staining (CFS) score of greater or equal to 4 in either eye by the National Eye Institute (NEI) /Industry Workshop Evaluation scale summed over 5 areas each with a 0-3 scoring scale,where 0 equals to normal,and 3 equals to severe with a maximum total score of 15. 7.Positive conjunctival staining, defined as a conjunctival lissamine green staining (CLGS) score of greater or equal to 4 in either eye by the National Eye Institute (NEI) /Industry Workshop Evaluation scale summed over 3 areas each with a 0-3 scoring scale, where 0 equals to normal and 3 equals to severe with a maximum total score of 18. 8. At least one of the following ocular symptoms scored at >=2, where a. 0 equals none and 4 equals to very severe/interferes with normal activities- photophobia, blurred vision, foreign body sensation, soreness or pain, itching, burning, dryness. 9.Ocular Surface Disease Index (OSDI) >=20;) 10.Best corrected visual acuity (BCVA) of 0.7 log MAR or better in each eye as assessed using an ETDRS chart 11.Normal lid position and closure.
Exclusion criteria
Exclusion criteria: 1.Present or history (in the preceding 6 months) of any systemic or ocular condition(s) that could possibly interfere with the interpretation of the study results; 2.Any disease of the eye leading to diffuse loss of conjunctiva; 3.Active anterior blepharitis; 4.A history or current evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccine, active or recent varicella viral disease of the cornea and/or conjunctiva; ocular rosacea; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye; 5.Current infections of the anterior segment or uveitis; 6.Uncontrolled systemic disease or the presence of any significant illness that can, in the judgment of the Investigator, interfere with interpretation of the study results; 7.Recent use (within 1 month) or anticipated use of temporary punctual plugs during the study; 8.Permanent occlusion of lacrimal puncta within 3 months of the study; 9.Subjects unwilling to discontinue contact lens wear at least one week prior to screening/ baseline visit and during the study duration; 10. Use of RESTASIS® (cyclosporine ophthalmic emulsion, 0.05%) or any other topical and/or systemic cyclosporine within 90 days before the study. 11.Previous treatment failure (lack of efficacy) with cyclosporine ophthalmic emulsion 0.05%. 12. Diagnosis of Sjogrenâ??s disease Ë? 5 years prior to the Screening Visit. 13.Clinical diagnosis or any history of seasonal and/or perennial allergic conjunctivitis. 14.Use of systemic or topical medications within 7 days prior to the Screening Visit or during the study period that are known to cause dry eye. 15. Corneal transplant. 16. Corneal refractive surgery within 6 months prior to the Screening Visit or postoperative refractive surgery symptoms of dryness that have not resolved; 17.Lasik surgery done within 6 months prior to screening visit. 18.Cataract surgery within 3 months prior to the screening visit.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in Corneal Staining ScoresTimepoint: 3 months and 6 months of treatment from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinically significant changes in the ocular examinationTimepoint: 6 Months;Global evaluation of overall effect of study medicationTimepoint: 3 month and 6month from baseline;Mean change in Conjunctival Staining ScoresTimepoint: 1, 2, 3, and 6 months of treatment from baseline;Mean change in Corneal Staining ScoresTimepoint: 1, 2, 3, and 6 months of treatment from baseline;Mean change in Ocular Surface Disease Index Score (OSDI) scoresTimepoint: 1, 2, 3, and 6 months from baseline ;Mean change in Schirmer Tear Test scores (without anaesthesia)Timepoint: 1, 2, 3, and 6 months from baseline ;Mean change in symptom scoresTimepoint: 1, 2, 3, and 6 months of treatment from baseline | — |
Countries
India
Contacts
Public ContactDr Shariq Anwar
JSS Medical Research India Private Limited
Outcome results
None listed